Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer

Nicholas Zaorsky, Robert B. Den, Laura A. Doyle, Adam P. Dicker, Mark D. Hurwitz

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

External beam radiation therapy (EBRT) combined with brachytherapy (BT) is an attractive treatment option for select patients with clinically localized prostate cancer. Either low- or high-dose rate BT may be combined with EBRT ('LDR-BT boost,' 'HDR-BT boost,' respectively). HDR-BT boost has potential theoretical benefits over LDR-BT boost or external beam radiation therapy monotherapy in terms of radiobiology, radiophysics and patient convenience. Based on prospective studies in this review, freedom from biochemical failure (FFBF) rates at 5 years for low-, intermediate- and high-risk patients have generally been 85-100%, 68-97%, 63-85%, respectively; late Radiotherapy and Oncology Group Grades 3 and 4 genitourinary and gastrointestinal toxicities are seen in <8% of patients. HDR-BT boost is now a relatively well-established treatment modality for certain intermediate-risk and high-risk prostate cancer patients, though limitations exist in drawing conclusions from the currently published studies.

Original languageEnglish (US)
Pages (from-to)751-763
Number of pages13
JournalExpert Review of Medical Devices
Volume10
Issue number6
DOIs
StatePublished - Nov 1 2013

Fingerprint

Brachytherapy
Radiotherapy
Prostatic Neoplasms
Technology
Oncology
Therapeutics
Dosimetry
Toxicity
Radiobiology
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Surgery
  • Biomedical Engineering

Cite this

Zaorsky, Nicholas ; Den, Robert B. ; Doyle, Laura A. ; Dicker, Adam P. ; Hurwitz, Mark D. / Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer. In: Expert Review of Medical Devices. 2013 ; Vol. 10, No. 6. pp. 751-763.
@article{388ecf997bb8408fa8d3d5b5b775d7dd,
title = "Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer",
abstract = "External beam radiation therapy (EBRT) combined with brachytherapy (BT) is an attractive treatment option for select patients with clinically localized prostate cancer. Either low- or high-dose rate BT may be combined with EBRT ('LDR-BT boost,' 'HDR-BT boost,' respectively). HDR-BT boost has potential theoretical benefits over LDR-BT boost or external beam radiation therapy monotherapy in terms of radiobiology, radiophysics and patient convenience. Based on prospective studies in this review, freedom from biochemical failure (FFBF) rates at 5 years for low-, intermediate- and high-risk patients have generally been 85-100{\%}, 68-97{\%}, 63-85{\%}, respectively; late Radiotherapy and Oncology Group Grades 3 and 4 genitourinary and gastrointestinal toxicities are seen in <8{\%} of patients. HDR-BT boost is now a relatively well-established treatment modality for certain intermediate-risk and high-risk prostate cancer patients, though limitations exist in drawing conclusions from the currently published studies.",
author = "Nicholas Zaorsky and Den, {Robert B.} and Doyle, {Laura A.} and Dicker, {Adam P.} and Hurwitz, {Mark D.}",
year = "2013",
month = "11",
day = "1",
doi = "10.1586/17434440.2013.841347",
language = "English (US)",
volume = "10",
pages = "751--763",
journal = "Expert Review of Medical Devices",
issn = "1743-4440",
publisher = "Expert Reviews Ltd.",
number = "6",

}

Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer. / Zaorsky, Nicholas; Den, Robert B.; Doyle, Laura A.; Dicker, Adam P.; Hurwitz, Mark D.

In: Expert Review of Medical Devices, Vol. 10, No. 6, 01.11.2013, p. 751-763.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Combining theoretical potential and advanced technology in high-dose rate brachytherapy boost therapy for prostate cancer

AU - Zaorsky, Nicholas

AU - Den, Robert B.

AU - Doyle, Laura A.

AU - Dicker, Adam P.

AU - Hurwitz, Mark D.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - External beam radiation therapy (EBRT) combined with brachytherapy (BT) is an attractive treatment option for select patients with clinically localized prostate cancer. Either low- or high-dose rate BT may be combined with EBRT ('LDR-BT boost,' 'HDR-BT boost,' respectively). HDR-BT boost has potential theoretical benefits over LDR-BT boost or external beam radiation therapy monotherapy in terms of radiobiology, radiophysics and patient convenience. Based on prospective studies in this review, freedom from biochemical failure (FFBF) rates at 5 years for low-, intermediate- and high-risk patients have generally been 85-100%, 68-97%, 63-85%, respectively; late Radiotherapy and Oncology Group Grades 3 and 4 genitourinary and gastrointestinal toxicities are seen in <8% of patients. HDR-BT boost is now a relatively well-established treatment modality for certain intermediate-risk and high-risk prostate cancer patients, though limitations exist in drawing conclusions from the currently published studies.

AB - External beam radiation therapy (EBRT) combined with brachytherapy (BT) is an attractive treatment option for select patients with clinically localized prostate cancer. Either low- or high-dose rate BT may be combined with EBRT ('LDR-BT boost,' 'HDR-BT boost,' respectively). HDR-BT boost has potential theoretical benefits over LDR-BT boost or external beam radiation therapy monotherapy in terms of radiobiology, radiophysics and patient convenience. Based on prospective studies in this review, freedom from biochemical failure (FFBF) rates at 5 years for low-, intermediate- and high-risk patients have generally been 85-100%, 68-97%, 63-85%, respectively; late Radiotherapy and Oncology Group Grades 3 and 4 genitourinary and gastrointestinal toxicities are seen in <8% of patients. HDR-BT boost is now a relatively well-established treatment modality for certain intermediate-risk and high-risk prostate cancer patients, though limitations exist in drawing conclusions from the currently published studies.

UR - http://www.scopus.com/inward/record.url?scp=84887790612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887790612&partnerID=8YFLogxK

U2 - 10.1586/17434440.2013.841347

DO - 10.1586/17434440.2013.841347

M3 - Review article

C2 - 24195459

AN - SCOPUS:84887790612

VL - 10

SP - 751

EP - 763

JO - Expert Review of Medical Devices

JF - Expert Review of Medical Devices

SN - 1743-4440

IS - 6

ER -